Evidence map›Paper›PMID 36794195›Full record

ArticleChemical science2023

Enantioselective Suzuki cross-coupling of 1,2-diboryl cyclopropanes.

Javier Teresa, Marina Velado, Roberto Fernández de la Pradilla, Alma Viso, Blanca Lozano, Mariola Tortosa

Abstract read
In one paragraph

Article in Chemical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Borylcyclopropanes: Synthetic Strategies and Applications.Angewandte Chemie (International ed. in English) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Tandem Diboration-Protoboration of Terminal Alkynes: A Practical Route to α-Substituted Alkenyl Boronates.Synlett : accounts and rapid communications in synthetic organic chemistry · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Javier TeresaOrganic Chemistry Department, Center for Innovation in Advanced Chemistry (ORFEO-CINQA), Universidad Autónoma de Madrid (UAM) 28049 Madrid Spain mariola.tortosa@uam.es.ORCID https://orcid.org/0000-0002-7305-0530
Marina VeladoInstituto de Química Orgánica General (IQOG), CSIC Juan de la Cierva 3 28006 Madrid Spain.
Roberto Fernández de la PradillaInstituto de Química Orgánica General (IQOG), CSIC Juan de la Cierva 3 28006 Madrid Spain.ORCID https://orcid.org/0000-0002-6633-8499
Alma VisoInstituto de Química Orgánica General (IQOG), CSIC Juan de la Cierva 3 28006 Madrid Spain.ORCID https://orcid.org/0000-0003-2622-4777
Blanca LozanoOrganic Chemistry Department, Center for Innovation in Advanced Chemistry (ORFEO-CINQA), Universidad Autónoma de Madrid (UAM) 28049 Madrid Spain mariola.tortosa@uam.es.ORCID https://orcid.org/0000-0001-5525-6458
Mariola TortosaOrganic Chemistry Department, Center for Innovation in Advanced Chemistry (ORFEO-CINQA), Universidad Autónoma de Madrid (UAM) 28049 Madrid Spain mariola.tortosa@uam.es.ORCID https://orcid.org/0000-0002-5107-0549

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, we describe the catalytic enantioselective cross-coupling of 1,2-bisboronic esters. Prior work on group specific cross coupling is limited to the use of geminal bis-boronates. This desymmetrization provides a novel approach to prepare enantioenriched cyclopropyl boronates with three contiguous stereocenters, that could be further derivatized through selective functionalization of the carbon-boron bond. Our results suggest that transmetallation, which is the enantiodetermining step, takes place with retention of stereochemistry at carbon.

Identifiers

PMID36794195
PMCPMC9906671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.